Skip to main content Accessibility help
×
×
Home

Treating depressive episodes or symptoms in patients with schizophrenia

  • Geeske van Rooijen (a1), Jentien Marloes Vermeulen (a1), Henricus Gerardus Ruhé (a1) (a2) (a3) and Lieuwe de Haan (a1)
Abstract

Depressive episodes or symptoms occur frequently in patients with schizophrenia and may have far-reaching consequences. Despite the high prevalence rate and clinical relevance of this comorbidity, knowledge about treatment options is still limited. The aim of this review is to provide an overview of the literature concerning treatment options for depressive episodes or symptoms in schizophrenia. Based on the current evidence, we present a stepwise treatment approach. The first step is to evaluate the current antipsychotic treatment of psychotic symptoms and consider lowering the dosage, since increased blockade of the dopamine D2 receptors may be associated with a worse subjective sense of well-being and dysphoria. A second step is to consider switching antipsychotics, since there are indications that some antipsychotics (including sulpiride, clozapine, olanzapine, aripiprazole, quetiapine, lurasidone, or amisulpride) are slightly more effective in reducing depressive symptoms compared to other antipsychotics or placebo. In the case of a persistent depressive episode, additional therapeutic interventions are indicated. However, the evidence is indecisive regarding the treatment of choice: either starting cognitive-behavioral therapy or adding an antidepressant. A limited number of studies examined the use of antidepressants in depressed patients with schizophrenia showing modest effectiveness. Overall, additional research is needed to determine the most effective treatment approach for patients with schizophrenia and depressive episodes.

Copyright
Corresponding author
*Address for correspondence: G. van Rooijen, Department of Psychiatry, Academic Medical Center, University of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands. (Email: g.vanrooijen@amc.nl)
Footnotes
Hide All

Shared last authorship.

Footnotes
References
Hide All
1. Buckley, PF, Miller, BJ, Lehrer, DS, Castle, DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009; 35(2): 383402.
2. Siris, SG. Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents. Am J Psychiatry. 2000; 157(9): 13791389.
3. Karvonen, K, Sammela, HL, Rahikkala, H, et al. Sex, timing, and depression among suicide victims with schizophrenia. Compr Psychiatry. 2007; 48(4): 319322.
4. Schwartz, RC, Cohen, BN. Psychosocial correlates of suicidal intent among patients with schizophrenia. Compr Psychiatry. 2001; 42(2): 118123.
5. Hawton, K, Sutton, L, Haw, C, Sinclair, J, Deeks, JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005; 187: 920.
6. Conley, RR, Ascher-Svanum, H, Zhu, B, Faries, DE, Kinon, BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007; 90(1–3): 186197.
7. Fervaha, G, Agid, O, Takeuchi, H, Foussias, G, Remington, G. Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study. Schizophr Res. 2013; 151(1–3): 203208.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, CA: American Psychiatric Association; 2013.
9. Heckers, S, Barch, DM, Bustillo, J, et al. Structure of the psychotic disorders classification in DSM–5. Schizophr Res. 2013; 150(1): 1114.
10. Helfer, B, Samara, MT, Huhn, M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016; 173(9): 876886.
11. Dauwan, M, Begemann, MJ, Heringa, SM, Sommer, IE. Exercise improves clinical symptoms, quality of life, global functioning, and depression in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2016; 42(3): 588599.
12. The National Institute for Health and Care Excellence (NICE). Psychosis and Schizophrenia in Adults. London: NICE; 2014. https://www.nice.org.uk/guidance/cg178/evidence/full-guideline-490503565. Accessed August 15, 2016.
13. Upthegrove, R, Marwaha, S, Birchwood, M. Depression and schizophrenia: cause, consequence or trans-diagnostic issue? Schizophr Bull. 2017; 43(2): 240244.
14. Castle, D, Bosnac, P. Depression and schizophrenia. Adv Psychiatr Treat. 2012; 18: 280288; http://apt.rcpsych.org/content/aptrcpsych/18/4/280.full.pdf. Accessed August 15, 2017.
15. Addington, D, Addington, J, Schissel, B. A depression rating scale for schizophrenics. Schizophr Res. 1990; 3(4): 247251.
16. Goldman, RG, Tandon, R, Liberzon, I, Greden, JF. Measurement of depression and negative symptoms in schizophrenia. Psychopathology. 1992; 25(1): 4956.
17. Lako, IM, Bruggeman, R, Knegtering, H, et al. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J Affect Disord. 2012; 140(1): 3847.
18. Hausmann, A, Fleischhacker, WW. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. Acta Psychiatr Scand. 2002; 106(2): 8396.
19. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
20. Olfson, M, Gerhard, T, Huang, C, Crystal, S, Stroup, TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015; 72(12): 11721181.
21. Baker, A, Bucci, S, Lewin, TJ, Richmond, R, Carr, VJ. Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies. Psychiatry Res. 2005; 134(3): 241250.
22. Birchwood, M, Iqbal, Z, Upthegrove, R. Psychological pathways to depression in schizophrenia: studies in acute psychosis, post psychotic depression and auditory hallucinations. Eur Arch Psychiatry Clin Neurosci. 2005; 255(3): 202212.
23. Anderson, G, Maes, M, Berk, M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuropsychopharmacology Biol Psychiatry. 2013; 42: 101114.
24. Meisenzahl, EM, Seifert, D, Bottlender, R, et al. Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. Eur Arch Psychiatry Clin Neurosci. 2010; 260(2): 127137.
25. Birchwood, M. Pathways to emotional dysfunction in first-episode psychosis. Br J Psychiatry. 2003; 182: 373375.
26. Tapp, A, Kilzieh, N, Wood, AE, Raskind, M, Tandon, R. Depression in patients with schizophrenia during an acute psychotic episode. Compr Psychiatry. 2001; 42(4): 314318.
27. Tandon, R, Goldman, RS, Goodson, J, Greden, JF. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia. Biol Psychiatry. 1990; 27(12): 13231326.
28. de Haan, L, van Bruggen, M, Lavalaye, J, Booij, J, Dingemans, PM, Linszen, D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry. 2003; 160(2): 303309.
29. de Haan, L, Lavalaye, J, Linszen, D, Dingemans, PM, Booij, J. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000; 157(6): 10191020.
30. Mizrahi, R, Rusjan, P, Agid, O, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry. 2007; 164(4): 630637.
31. Tandon, R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry. 2011; 72(Suppl 1): 48.
32. Voruganti, L, Awad, AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl). 2004; 171(2): 121132.
33. Furtado, V, Srihari, V, Kumar, A. Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Database Syst Rev. 2008;1): CD005377. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171386/. Accessed August 15, 2017.
34. Leucht, S, Arbter, D, Engel, RR, Kissling, W, Davis, JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009; 14(4): 429447.
35. Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373(9657): 3141.
36. Gotzsche, P. Are new drugs for schizophrenia better than old ones? Lancet. 2009; 373(9671): 1248; author reply 12491250.
37. Johnsen, E. Review: second generation antipsychotics are a heterogeneous drug class. Evid Based Ment Heal. 2009; 12(3): 90.
38. Lieberman, JA, Stroup, TS, McEvoy, JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 12091223.
39. Addington, DE, Mohamed, S, Rosenheck, RA, et al. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry. 2011; 72(1): 7580.
40. Nasrallah, HA, Cucchiaro, JB, Mao, Y, Pikalov, AA, Loebel, AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2015; 20(2): 140147.
41. Galling, B, Roldán, A, Hagi, K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017; 16(1): 7789.
42. Falkai, P, Wobrock, T, Lieberman, J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2005; 6(3): 132191.
43. Werkgroep Richtlijn Schizofrenie. Multidisciplinaire Richtlijn Schizofrenie. Utrecht: Nederlandse Vereniging voor Psychiatrie; 2012.
44. Nikiforuk, A. Targeting the serotonin 5-HT7 receptor in the search for treatments for CNS disorders: rationale and progress to date. CNS Drugs. 2015; 29(4): 265275.
45. Bétry, C, Etiévant, A, Oosterhof, C, Ebert, B, Sanchez, C, Haddjeri, N. Role of 5-HT3 receptors in the antidepressant response. Pharmaceuticals. 2011; 4(4): 603629.
46. Meltzer, HY, Massey, BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011; 11(1): 5967.
47. Garnock-Jones, KP. Brexpiprazole: a review in schizophrenia. CNS Drugs. 2016; 30(4): 335342.
48. Correll, CU, Skuban, A, Hobart, M, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res. 2016; 174(1–3): 8292.
49. Rosenheck, RA. Effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv. 2005; 56(1): 8592.
50. Whitehead, C, Moss, S, Cardno, A, Lewis, G, Furtada, V. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev. 2002;(2): CD002305. doi: 10.1002/14651858.CD002305.
51. Terevnikov, V, Joffe, G, Stenberg, JH. Randomized controlled trials of add-on antidepressants in schizophrenia. Int J Neuropsychopharmacol. 2015; 18(9): 114.
52. Mao, YM, Zhang, MD. Augmentation with antidepressants in schizophrenia treatment: Benefit or risk. Neuropsychiatr Dis Treat. 2015; 11: 701713; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370910/. Accessed August 15, 2017.
53. Kishi, T, Hirota, T, Iwata, N. Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials. Eur Arch Psychiatry Clin Neurosci. 2013; 263(8): 633641.
54. Kishi, T, Iwata, N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol. 2014; 17(2): 343354.
55. van Dijk, HG, Dapper, EA, Vinkers, CH. SSRIs en depressieve klachten bij schizofrenie: een systematische review [SSRIs and depressive symptoms in schizophrenia: a systematic review] [in Dutch]. Ned Tijdschr Psychiatr. 2017; 59(1): 4046.
56. Spina, E, de Leon, J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2014; 10(5): 721746.
57. Flockhart, DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Bloomington: Indiana University School of Medicine; 2007. http://medicine.iupui.edu/clinpharm/ddis/clinical-table. Accessed April 25, 2017.
58. Hiemke, C, Baumann, P, Bergemann, N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011; 44(6): 195235.
59. Leucht, S, Helfer, B, Dold, M, Kissling, W, McGrath, JJ. Lithium for schizophrenia (Review ). Cochrane Database Syst Rev. 2015;10): CD003834. doi: 10.1002/14651858.CD003834.pub3.
60. Wang, Y, Xia, J, Helfer, B, Li, C, Leucht, S. Valproate for schizophrenia. Cochrane Database Syst Rev. 2016;(11): CD004028. doi: 10.1002/14651858.CD004028.pub4.d.
61. De Hert, M, Detraux, J, van Winkel, R, Yu, W, Correll, CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012; 8(2): 114126.
62. Wykes, T, Steel, C, Everitt, B, Tarrier, N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008; 34(3): 523537.
63. Jones, C, Hacker, D, Cormac, I, Meaden, A, Irving, CB. Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database Syst Rev. 2012; 4(4): CD008712. doi: 10.1002/14651858.CD008712.pub2.
64. Tharyan, P, Adams, C. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev. 2005;(2): CD000076. doi: 10.1002/14651858.CD000076.pub2.
65. Dougall, N, Maayan, N, Soares-Weiser, K, McDermott, L, McIntosh, A. Transcranial magnetic stimulation for schizophrenia. Cochrane Database Syst Rev. 2015;(8): CD006081. doi: 10.1002/14651858.CD006081.pub2.
66. Harvey, PD, Espaillat, S.. Suicide in schizophrenia. In Koslow SH, Ruiz P, Nemeroff CB, eds. A Concise Guide to Understanding Suicide Epidemiology: Pathophysiology and Prevention, 1st ed.. Cambridge: Cambridge University Press; 2014: 406.
67. Palmer, BA, Pankratz, VS, Bostwick, JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005; 62(3): 247253.
68. Meltzer, HY, Alphs, L, Green, AI, et al. Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry. 2003; 60(1): 8291.
69. Hennen, J, Baldessarini, RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res. 2005; 73(2–3): 139145.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed